Chronic atropine administration diminishes the contribution of vasoactive intestinal polypeptide to heart rate regulation.
Vasoactive intestinal polypeptide (VIP) is implicated in the modulation of vagal effects on the heart rate. In this study, the impact of acute and chronic atropine administration on VIP levels in rat heart atria was investigated in relation to heart rate in the course of vagus nerves stimulation. Anaesthetised control and atropinised (10 mg/kg/day for 10 days) rats pretreated with metipranolol and phentolamine that were either given or not a single dose of atropine were subjected to bilateral vagus nerve stimulation (30 min: 0.7 mA, 20 Hz, 0.2 ms). VIP concentrations in the atria were determined after each stimulation protocol. In control rats with or without single atropine administration, the heart rate upon vagal stimulation was higher than in atropinised animals with or without single atropine dose, respectively. VIP concentrations in the control atria were significantly decreased after the stimulation; the decrease was comparable both in the absence and presence of a single dose of atropine. Compared to controls, VIP levels were significantly decreased after chronic atropine treatment and they were not further reduced by vagal stimulation and single atropine administration. Administration of VIP antagonist completely abolished the differences in the heart rate upon vagal stimulation between control and atropinised groups. In conclusion, the data indicate that chronic atropine administration affects VIP synthesis in rat heart atria and consequently it modifies the heart rate regulation.
Kuncová
J
J
Department of Physiology, Charles University, Plzen, Czech Republic. jitka.kuncova@lfp.cuni.cz
Faitová
S
S
Capouch
J
J
Stengl
M
M
Slavíková
J
J
D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D000818:Animals; D001285:Atropine / Q000008:administration & dosage*; D004558:Electric Stimulation; D006325:Heart Atria / Q000294:innervation* / Q000378:metabolism; D006339:Heart Rate / Q000187:drug effects*; D006727:Hormone Antagonists / Q000494:pharmacology*; D014290:Metipranolol / Q000494:pharmacology; D018727:Muscarinic Antagonists / Q000008:administration & dosage*; D010646:Phentolamine / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D011976:Receptors, Muscarinic / Q000187:drug effects / Q000378:metabolism; D013997:Time Factors; D014630:Vagus Nerve / Q000187:drug effects* / Q000378:metabolism; D014660:Vasoactive Intestinal Peptide / Q000037:antagonists & inhibitors / Q000378:metabolism* / Q000494:pharmacology
D000317:Adrenergic alpha-Antagonists; D000319:Adrenergic beta-Antagonists; D006727:Hormone Antagonists; D018727:Muscarinic Antagonists; D011976:Receptors, Muscarinic; C048507:vasoactive intestinal peptide, 4-chloro-Phe(6)-Leu(17)-; D014660:Vasoactive Intestinal Peptide; D001285:Atropine; D014290:Metipranolol; D010646:Phentolamine